Fei Ye

Fei Ye

Auto-generated profile, based on publicly available information

Fei Ye

Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YHYuan Hu
Yuan Hu
JZJieqiong Zhou
Jieqiong Zhou
FYFei Ye
Fei Ye
HXHuabao Xiong
Huabao Xiong
LPLiang Peng
Liang Peng
DZDavid Y. Zhang
David Y. Zhang
Post-translational modifications have been identified to be of great importance in cancers and lysine acetylation, which can attract the multifunctional transcription factor BRD4, has been identified as a potential therapeutic target. In this paper, we identify that BRD4 has an important role in colorectal cancer; and that its inhibition substantially wipes out tumor cells. Treatment with inhibitor MS417 potently affects cancer cells, although such effects were not always outright necrosis or apoptosis. We report that BRD4 inhibition also limits distal metastasis by regulating several key proteins in the progression of epithelial-to-mesenchymal transition (EMT). This effect of BRD4 inhibitor is demonstrated via liver metastasis in animal model as well as migration and invasion experiments in vitro. Together, our results demonstrate a new application of BRD4 inhibitor that may be of clinical use by virtue of its ability to limit metastasis while also being tumorcidal.

1 January 2009 in Cell Division
Verified
Journal Article
Open access
PDF file
DZDavid Y Zhang
David Y Zhang
FYFei Ye
Fei Ye
LGLing Gao
Ling Gao
XLXiaoliang Liu
Xiaoliang Liu
XZXin Zhao
Xin Zhao
PLPeng Lee
Peng Lee
Cancer is a multifaceted disease that results from dysregulated normal cellular signaling networks caused by genetic, genomic and epigenetic alterations at cell or tissue levels. Uncovering the underlying protein signaling network changes, including cell cycle gene networks in cancer, aids in understanding the molecular mechanism of carcinogenesis and identifies the characteristic signaling network signatures unique for different cancers and specific cancer subtypes. The identified signatures can be used for cancer diagnosis, prognosis, and personalized treatment. During the past several decades, the available technology to study signaling networks has significantly evolved to include such platforms as genomic microarray (expression array, SNP array, CGH array, etc.) and proteomic analysis, which globally assesses genetic, epigenetic, and proteomic alterations in cancer. In this review, we compared Pathway Array analysis with other proteomic approaches in analyzing protein network involved in cancer and its utility serving as cancer biomarkers in diagnosis, prognosis and therapeutic target identification. With the advent of bioinformatics, constructing high complexity signaling networks is possible. As the use of signaling network-based cancer diagnosis, prognosis and treatment is anticipated in the near future, medical and scientific communities should be prepared to apply these techniques to further enhance personalized medicine.

1 June 2014 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
MCMiao Cui
Miao Cui
NCNicholas Chan
Nicholas Chan
MLMomo Liu
Momo Liu
KTKhanh Thai
Khanh Thai
JMJoanna Malaczynska
Joanna Malaczynska
FYFei Ye
Fei Ye
Evaluation of the Cobas 4800 test demonstrated that Cobas had a low rate of cross-reactivity with low-risk human papillomavirus (lrHPV), a 3.74% disconcordance rate between prealiquots and postaliquots, and failure rates of 4.57% and 1.16%, respectively, after vortexing and swirling. This study demonstrated that the Cobas test has good sensitivity, accuracy, and reproducibility for detecting 14 high-risk HPV (hrHPV) genotypes.

13 November 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CSChang Shu
Chang Shu
ZLZitao Liu
Zitao Liu
LCLifeng Cui
Lifeng Cui
CWChengguo Wei
Chengguo Wei
SWShuwen Wang
Shuwen Wang
FYFei Ye
Fei Ye
Preeclampsia is a multi-system disorder involved in pregnancy without an effective treatment except delivery. The precise pathogenesis of this complicated disorder is still not completely understood. The objective of this study is to evaluate the alterations of protein expression and phosphorylations that are important in regulating placental cell function in preterm and term preeclampsia. Using the Protein Pathway Array, 38 proteins in placental tissues were found to be differentially expressed between preterm preeclampsia and gestational age matched control, while 25 proteins were found to be expressed differentially between term preeclampsia and matched controls. Among these proteins, 16 proteins and their associated signaling pathways overlapped between preterm and term preeclampsia, suggesting the common pathogenesis of two subsets of disease. On the other hand, many proteins are uniquely altered in either preterm or term preeclampsia and correlated with severity of clinical symptoms and outcomes, therefore, providing molecular basis for these two subsets of preeclampsia. Furthermore, the expression levels of some of these proteins correlated with neonatal small for gestational age (PAI-1 and PAPP-A) and adverse outcomes (Flt-1) in women with preterm preeclampsia. These proteins could potentially be used as candidate biomarkers for predicting outcomes of preeclampsia.

1 May 2014 in The American Journal of Pathology
Verified
Journal Article
Closed access
GLGuodong Lian
Guodong Lian
CWChengguo Wei
Chengguo Wei
DWDaguang Wang
Daguang Wang
MCMiao Cui
Miao Cui
ZWZhiqing Wang
Zhiqing Wang
FYFei Ye
Fei Ye

1 January 2014
Verified
Journal Article
Closed access
WLWei Liu
Wei Liu
YWYong Wu
Yong Wu
LWLibo Wang
Libo Wang
LGLing Gao
Ling Gao
YWYingping Wang
Yingping Wang
FYFei Ye
Fei Ye